Ketamine at Home: IV, IM, Subq, or Sublingual? A Physician's Honest Take

If you have been researching ketamine therapy for depression, anxiety, PTSD, or chronic pain, you have probably typed some variation of "ketamine at home" into Google. That phrase covers a lot of ground, and the route of administration is the single most important variable that determines what kind of clinical setup a legitimate provider can actually offer.

I am Dr. Ben Soffer, board-certified in internal medicine, licensed in Florida and New Jersey. I prescribe ketamine via telehealth, and I have strong opinions about which routes belong at home and which do not. This post is the explainer I wish more clinics would write.

TL;DR

• Sublingual ketamine (troches or rapid-dissolve tablets). Yes, appropriate for home use under physician supervision. This is what I prescribe.
• IV ketamine. No. Belongs in a clinical setting with continuous monitoring.
• IM ketamine. I do not prescribe it for home use, and the reasons are mostly about the parenteral workflow, not the timing.
• Subcutaneous (subq) ketamine. Mostly used for chronic pain in palliative contexts. Not appropriate for psychiatric self-administration at home.
• Compounded intranasal ketamine. Rarely useful for home psychiatric use. Faster onset than sublingual creates more habit-forming risk. The exception is supervised chronic-pain protocols where rapid breakthrough-pain relief is the clinical goal.

The rest of this post is the why behind each of those answers, in plain language.

Why the route matters

Ketamine is a dissociative anesthetic. At sub-anesthetic doses, the kind used for depression and anxiety, it produces a brief altered state of consciousness lasting roughly 45 to 90 minutes depending on the route, with sensory shifts, time distortion, and a softening of the usual ego boundaries that many patients describe as therapeutically useful.

Two things make the route matter:

1. The onset and peak of effect. IV ketamine peaks within minutes. IM peaks at roughly 5 to 15 minutes. Subq is somewhere in between. Intranasal peaks at 10 to 20 minutes. Sublingual climbs slowly over 20 to 40 minutes and peaks at roughly an hour.

For sublingual, that slower curve means a patient takes the dose, settles their environment, sends a "starting now" message to their sitter, and is lying down well before any meaningful effect appears. The format quietly enforces a preparation window.

2. Dosing precision and bioavailability. Sublingual ketamine has a bioavailability of roughly 25 to 30 percent, with patient-to-patient variability. IM is much higher. Intranasal sits between the two depending on formulation. High bioavailability sounds like a feature, until you realize the small absorption buffer in sublingual administration is exactly what gives the route its margin. Small dosing errors sublingually produce small systemic effects. The same proportional error on a parenteral route lands the full magnification straight into the bloodstream.

This is why sublingual is the format engineered for safe at-home use, and the others are not. The pharmacokinetics are not a side note. They are the whole reason routes get assigned to settings.

IV ketamine at home: why I do not prescribe it

Intravenous ketamine has the strongest evidence base for treatment-resistant depression. It is also the most monitoring-intensive route.

In a properly run clinic, IV sessions involve continuous blood pressure monitoring (ketamine reliably raises BP and heart rate), pulse oximetry, an IV line that stays in for the duration, a nurse or physician in the room or immediately available, and resuscitation equipment within reach. Patients are screened for cardiovascular risk before the first infusion.

None of that is possible in a patient's home. No patient can safely self-cannulate, monitor their own blood pressure during dissociation, or respond appropriately to a hypertensive episode while in the middle of a ketamine experience.

A small number of telehealth providers in some jurisdictions have offered IV at home with a visiting nurse. Even in that model, which is rare and expensive, the safety floor is far higher than what any unaccompanied home setup can replicate. For self-administered home use without a clinician in the room, IV is not on the table.

IM ketamine at home: why I do not prescribe it

Intramuscular ketamine is a single injection into a muscle, typically the deltoid or the lateral thigh. It is used in clinic for procedural sedation and increasingly for psychiatric ketamine sessions because it is faster to set up than an IV. The onset gives the patient a similar preparation window to sublingual, so the "you would be impaired before you finished setting up" concern that applies to IV does not apply here. That timing argument is not why I avoid it.

The real reasons against IM at home are about the parenteral workflow and the operational reality of keeping a controlled-substance vial in a household.

First, the injection itself is not trivial. Ketamine for injection has an acidic formulation, which makes IM injection genuinely uncomfortable. Clinics often buffer it or use slow-push technique to reduce the burn. A self-injecting patient on their first session at home is being asked to overcome a real "I do not want to do this" reflex, into a muscle they have likely never injected before. Without training, technique errors can produce bruising, irritation near nerves at certain sites, or accidental injection into a vessel rather than muscle. The clinical staff who would normally handle this are not in the room.

Second, the needle handling and household-safety problem. Each session means working with a vial of a DEA Schedule III controlled substance, an appropriate needle, a sharps container for safe disposal, and a secure storage plan for the remaining supply between sessions. None of that is hard in a clinical workflow. At home it is a meaningful operational burden, with real risks. Needlestick injuries to the patient or a family member. Kids or pets finding a vial or sharps container. Partners or housemates with substance-use history finding the supply. Sublingual troches in foil packaging sidestep every part of this. They are easier to lock up, easier to track, harder to misuse, and have no sharps footprint.

Third, the dosing-precision problem. Parenteral ketamine for psychiatric use is dosed by weight, drawn from vials of varying concentration. The volume math is straightforward in a pharmacy or clinic setting and easy to fumble at home, especially on the first few sessions. Pre-measured sublingual troches eliminate the math entirely. A proportional dosing error orally is usually recoverable. The same proportional error IM hits the bloodstream within minutes and offers little opportunity to course-correct.

If you are being offered IM ketamine at home by a provider, ask them: who reviewed your cardiovascular screen, who is reachable during the session, and what is their protocol if something goes wrong. The answers will tell you whether you are working with a real clinic or a shipping operation with a medical license rented for cover.

Subcutaneous ketamine at home

Subcutaneous ketamine is mostly used in palliative care and chronic pain practice, sometimes as a continuous infusion via a small pump for cancer pain that other approaches have not controlled. It is a valid clinical route in those settings.

It is not a route used for outpatient psychiatric ketamine therapy, and I do not know of any legitimate telehealth provider offering it for psychiatric indications. If you have seen it advertised that way, treat the advertisement with skepticism. The same self-administration, dosing-precision, and monitoring concerns from the IM section apply.

The exception worth knowing about is hospice patients receiving subq ketamine through a home infusion service. That is a fundamentally different clinical setup with a home health nurse, palliative care physician oversight, and a controlled medication pump. It is not "ketamine therapy at home" in the way patients searching this topic usually mean.

Compounded intranasal ketamine: rarely useful at home, chronic pain exception

Intranasal ketamine prepared by a compounding pharmacy is a real format. It is different from Spravato (the FDA-approved esketamine nasal spray), which is restricted under a federal program to in-clinic administration only. Compounded intranasal racemic ketamine can technically be prescribed for home use. I rarely do.

Two reasons.

First, the habit-forming risk is meaningfully higher than sublingual. A nasal spray takes seconds to administer and effects peak in 10 to 20 minutes. Each spray delivers a small dose. The combination of fast onset, easy administration, and the absence of a natural pause between doses creates a use pattern that resembles, to the brain's reward system, the way addictive nasal substances are typically misused. Sublingual ketamine works differently. The troche takes 5 to 10 minutes to dissolve. The onset is gradual. There is no natural impulse to take "one more" mid-session because the patient is already in the experience by the time they would think to. The dosing interval is enforced by the format itself. For a Schedule III controlled substance being used for a mood disorder, the route that paces itself is the safer one.

Second, intranasal ketamine does not solve a problem sublingual cannot already solve for psychiatric use. Patients respond to both routes at comparable rates in the literature. Sublingual is cheaper to compound, easier to ship, and the slower onset is therapeutically equivalent or better for most depression and anxiety indications.

The clinical exception is chronic pain, particularly breakthrough pain. Some chronic-pain protocols use intranasal ketamine specifically because the rapid 10 to 20 minute onset is the point. A patient with a known cancer-pain or neuropathic-pain pattern who experiences a sudden flare benefits from a route that takes effect quickly. In that supervised setting, with a limited prescription supply, intranasal can be the right tool. The risk-benefit calculation is different when the goal is rapid pain relief rather than a planned psychiatric session.

For psychiatric ketamine at home, when no breakthrough-pain dynamic is in play, the slower sublingual route is the better default. That is what I prescribe.

Sublingual ketamine: why this is what I prescribe

Sublingual ketamine, also called buccal ketamine when the troche is held against the cheek, is what I prescribe to nearly every patient I see for at-home ketamine therapy.

Patients receive a compounded troche or rapid-dissolve tablet from a DEA-registered compounding pharmacy. They take a single dose, holding it under the tongue or against the cheek for several minutes, then either swallow the saliva or spit (different protocols vary). Onset is gradual, 20 to 40 minutes to peak. The effect lasts roughly 60 to 90 minutes.

The reasons this format works at home:

• No needles. No self-injection, no sharps disposal, no chain-of-custody questions about parenteral controlled substances.
• Slow onset. Patient is fully oriented at the time of administration. Theysend a "starting now" message to their peer support, get into position, dim the lights, and the experience begins after they are already settled.
• Lower peak effect for a given dose. The slower absorption curve produces a gentler peak than IM or IV at equivalent total absorbed dose. Patients can still reach therapeutic dissociation, just on a smoother trajectory.
• Recoverable dosing errors. If a patient absorbs less than the prescribed dose because they swallowed early, the experience is gentler than intended, not dangerously stronger.
• Format-enforced dose pacing. The dissolution time prevents the take-another-dose pattern that nasal formats invite. The route quietly does some of the harm-reduction work the prescriber would otherwise have to do with patient education alone.
• Practical for repeat sessions. Patients can run a 4 to 6 session course over several weeks without needing a clinic visit each time.

There is also a peer support requirement, what I call a "sitter," that is non-negotiable for every patient. The sitter is a sober adult who agrees to be physically present for the session, monitor the patient, and call for help if something goes wrong. This is the human-monitoring layer that replaces the clinical-monitoring layer you would get in a ketamine clinic.

The combination, sublingual route, peer support present, physician available by phone, screening done in advance, is the safety architecture that makes at-home ketamine medicine and not a shipping operation.

Red flags when evaluating at-home ketamine providers

A short checklist for patients evaluating any at-home ketamine offering:

• Does the provider require a peer support or sitter to be present? Anyone who waves this requirement is cutting the human-monitoring layer that makes at-home ketamine safe. Walk away.
• Did you have a real video consultation with a licensed physician before being prescribed? Not a form, not a chatbot screen. A physician who looked at your medical history and asked questions. This is the legal floor for telehealth ketamine.
• Is the route IV, IM, subq, or intranasal? If yes, the provider should have a clear answer about monitoring, dosing precision, and emergency protocols. If they are shipping parenteral or nasal kits with self-administration instructions and no on-call physician, that is the operation I would avoid.
• Is the pharmacy DEA-registered and named? You should receive a prescription from a known compounding pharmacy with a verifiable license. Generic "we ship from a pharmacy partner" without a name is concerning.
• Is the provider licensed in your state? Ketamine is prescribed under the prescriber's state license. If you are in Florida and the prescribing physician is licensed only in California, the telehealth setup is on shaky legal ground.

Frequently asked questions

Can I get IV ketamine therapy at home in Florida or New Jersey?

Not safely, and not legitimately. IV ketamine requires continuous cardiovascular monitoring and immediate access to resuscitation equipment. No realistic home setup provides that. The few providers offering at-home IV ketamine do so with a visiting nurse, which is still a far higher safety floor than any self-administered version. For at-home telehealth without a nurse present, sublingual is the only appropriate route.

Is IM ketamine at home illegal?

It exists in a regulatory gray zone in many states. The DEA has not directly ruled on telehealth-prescribed home IM ketamine, and individual state pharmacy boards have varied positions. The fact that something is available does not mean it is a defensible standard of care. I do not prescribe it.

Why do you not prescribe intranasal ketamine for depression?

Two reasons. The faster onset creates more habit-forming risk than sublingual, because patients can take another dose without much friction and the brain's reward system patterns the use the way it patterns other fast-onset substances. And clinically, intranasal does not outperform sublingual for psychiatric use at comparable doses. The chronic-pain context is different. If you are a pain patient who needs rapid breakthrough-pain coverage, the route trade-off changes.

Is sublingual ketamine less effective than IV?

The literature shows IV ketamine has the strongest evidence base for treatment-resistant depression, with response rates around 60 to 70 percent in carefully selected patients. Sublingual ketamine has fewer head-to-head studies, but the response rates I see clinically, in selected patients with appropriate support, are in a similar range. Some patients respond better to one route than another. The route choice is also influenced by what can safely be delivered in the patient's setting.

What if I tried sublingual and it did not work, should I try IV?

Possibly, and that is a conversation to have with a ketamine clinic that offers in-person infusions. A handful of patients do not respond to sublingual at therapeutic doses and do respond to IV at the same total absorbed dose, possibly because the rapid peak triggers a different neuroplastic response. If sublingual has not worked after a properly-dosed course, an in-clinic IV consultation is reasonable.

How do I know if at-home sublingual ketamine is right for me?

The five-minute eligibility assessment covers the medical and situational factors I review on every consultation. It is free, takes about five minutes, and gets you to a clear yes, no, or "needs a conversation" answer before you commit to anything.

---

The honest summary. The at-home ketamine telehealth space is genuinely useful medicine for the right patients in the right format, and a regulatory gray zone in the wrong formats. Sublingual ketamine, physician-prescribed, with peer support present and proper screening, is where the safe-and-effective center lives. Everything else either belongs in a clinic or should not exist as an at-home option.

If you are considering ketamine therapy and you want to start with the route I actually trust, the eligibility assessment is the front door.